R&D | Cutting-edge science and innovative research

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Roche's AI-powered digital pathology open environment in action

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

News

Data builds behind Bayer's Kerendia in kidney disease

Bayer's Kerendia has hit the spot in another phase 3 trial that could fuel its already rapid growth as a chronic kidney disease treatment.

News

Yellow balloons with smiling faces drawn on them in black ink

J&J says Inlexzo follow-up 'promising' in bladder cancer

Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.

News

Roche eyeing $7bn deal to buy Roivant drug; report

Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco

News

EU sets up €100m fund to tackle health threats

The EU has set aside a €100 million block of financing for small- and medium-sized enterprises working on projects that could tackle public health threats, including emerg

News

Tenpoint raises $70m for vision loss therapies

UK-headquartered start-up Tenpoint Therapeutics has reeled in a commendable $70 million in first-round financing that will be used to develop its cell-based therapies for

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Roche accelerates AI adoption with NVIDIA deal

Roche has ramped up its investment in NVIDIA's AI chips, launching a hybrid-cloud AI factory that it believes is the largest in the pharma industry.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Women in life sciences: Why female representation still lags...

pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata, about being a woman in STEM.

R&D

Changing Faces: Pharma and biotech, February 2026

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month.

R&D

A complex biological landscape of protein function unlocked ...

Promise Bio’s advanced AI-driven system integrates proteomics and multi-omics data, focusing on PTMs to identify unique biomarkers % disease pathways.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

Video

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D